Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Cancer Detection Clear all
Terminated No phase listed Observational

Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy

NCT04234399
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Fluciclovine PET/CT using a digital PET/CT
Diagnostic Test
Lead sponsor
University of Vermont
Other
Eligibility
40 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Jun 27, 2026, 1:56 AM EDT
Completed Phase 3 Interventional

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

NCT02940262
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
Radiation · Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
1,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Jun 27, 2026, 1:56 AM EDT
Terminated No phase listed Observational

Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers

NCT03073473
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer, Metastatic Melanoma, Metastatic Prostate Cancer
Interventions
NantHealth GPS Cancer Test
Diagnostic Test
Lead sponsor
Cota Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
East Brunswick, New Jersey • Freehold, New Jersey • Hackensack, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jun 27, 2026, 1:56 AM EDT
Active, not recruiting Not applicable Interventional

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

NCT05628363
View directory record Official record
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy
Device · Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 27, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study

NCT02967458
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Perflutren Lipid Microsphere Intravenous Suspension
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Jun 27, 2026, 1:56 AM EDT
Terminated Phase 1 Interventional Results available

11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression

NCT04927663
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Solid Tumor, Adult, Solid Tumor, Metastatic Castration-resistant Prostate Cancer
Interventions
Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, 11C-YJH08, Optional Tumor Biopsy
Procedure · Drug
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Jun 27, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

NCT03113617
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Andrei Iagaru
Other
Eligibility
19 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jun 27, 2026, 1:56 AM EDT
Completed No phase listed Observational

For Cause Prostate Biopsy in REDUCE Population Trial

NCT01529086
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
6,608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Jun 27, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

NCT03081884
View directory record Official record
Conditions
Cancer
Interventions
FACBC PET-CT Imaging
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Jun 27, 2026, 1:56 AM EDT
Completed No phase listed Observational

Markers for Early Detection of Prostate Cancer

NCT00340717
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years to 75 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 27, 2026, 1:56 AM EDT
Recruiting Not applicable Interventional

Transrectal Ultrasound Robot-Assisted Prostate Biopsy

NCT02871726
View directory record Official record
Conditions
Prostate Cancer
Interventions
TRUS-Robot, TRUS biopsy
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 27, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

FACBC PET/CT for Recurrent Prostate Cancer

NCT00562315
View directory record Official record
Conditions
Prostate Cancer
Interventions
FACBC, ProstaScinct
Drug · Other
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Jun 27, 2026, 1:56 AM EDT
Completed Early Phase 1 Interventional

Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer

NCT00956163
View directory record Official record
Conditions
Bone Metastases, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
magnetic resonance imaging, fluorine F 18 sodium fluoride, positron emission tomography, computed tomography, technetium Tc 99m methylene diphosphonate, laboratory biomarker analysis
Procedure · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Jun 27, 2026, 1:56 AM EDT
Terminated Phase 1Phase 2 Interventional

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

NCT03441464
View directory record Official record
Conditions
Prostate Cancer, Neoplasm, Residual
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Jun 27, 2026, 1:56 AM EDT
Terminated Not applicable Interventional Results available

Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer

NCT02307552
View directory record Official record
Conditions
Prostate Cancer
Interventions
UreScan
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Jun 27, 2026, 1:56 AM EDT
Withdrawn Phase 2 Interventional

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

NCT04910425
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jun 27, 2026, 1:56 AM EDT
Recruiting No phase listed Observational

Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer

NCT07645391
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 27, 2026, 1:56 AM EDT
Active, not recruiting Phase 2 Interventional

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

NCT03471650
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 27, 2026, 1:56 AM EDT
Not listed Not applicable Interventional

MyProstateScore Equivalency With and Without DRE

NCT05700370
View directory record Official record
Conditions
Prostate Cancer
Interventions
MyProstateScore
Diagnostic Test
Lead sponsor
LynxDx
Industry
Eligibility
45 Years and older · Male only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jun 27, 2026, 1:56 AM EDT
Recruiting No phase listed Observational

Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI

NCT04992728
View directory record Official record
Conditions
Prostate Cancer
Interventions
Restricted Spectrum Magnetic Resonance Imagining
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jun 27, 2026, 1:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

NCT02678351
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
68Ga-PSMA-11, Magnetic resonance imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jun 27, 2026, 1:56 AM EDT
Terminated No phase listed Observational

MRI Before Biopsy in Diagnosing Patients With Prostate Cancer

NCT02131207
View directory record Official record
Conditions
Prostate Cancer
Interventions
magnetic resonance imaging, prostate biopsy
Device · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Jun 27, 2026, 1:56 AM EDT
Completed Not applicable Interventional

Optical Tomography in Prostate Cancer

NCT03215992
View directory record Official record
Conditions
Prostate Cancer
Interventions
Diffuse Optical Tomography (DOT) System
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Jun 27, 2026, 1:56 AM EDT
Recruiting No phase listed Observational

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

NCT07543757
View directory record Official record
Conditions
Prostate Cancer Detection
Interventions
Proclarix
Diagnostic Test
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 27, 2026, 1:56 AM EDT